Statement by the President of the Republic at the Seqens factory, Villeneuve-la-Garenne.

France Emmanuel Macron · President of France

28 August 2020 · Seqens factory, Villeneuve-la-Garenne, France

Context
Macron visited the Seqens pharmaceutical factory in Villeneuve-la-Garenne on August 28, 2020, to highlight France's industrial reshoring strategy amid the COVID-19 pandemic.
Main themes
Pharmaceutical reshoring, French industrial policy, COVID-19 economic recovery, Seqens company, active pharmaceutical ingredients, economic reforms, apprenticeship and youth employment, recovery plan, supply chain sovereignty, healthcare preparedness
Duration
~14 min
49th percentile
Words
1,704
49th percentile
Sentences
61
40th percentile
Readability
47
54th percentile
Grade
13.6
63rd percentile
Syntax
3.29
82nd percentile
Vocabulary
2.24
59th percentile

Translated from French

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Economic 85%84%
  • Institutional 7%7%
  • Ceremonial 5%5%
  • Social 3%3%
  • Geopolitical 0%0%
  • Technological 0%0%
  • Environmental 0%0%
  • Not in focus 2%

61 sentences in 17 paragraphs

Ladies and Gentlemen,

First of all, I want to thank the Mayor for welcoming us to his municipality, and the building behind me illustrates the historical importance of this pharmaceutical sector, right here in this municipality, since the end of the 19th century, pharmaceuticals have been produced here, what is needed to care for our fellow citizens, and this shows the importance of this industry in this territory and right here. In this period where we must continue to fight against the virus to slow its spread, to also learn to live with Covid-19 and in a context where decisions have been made to prepare for the school year and to continue economic activity in all sectors and support struggling sectors.

With the Minister of Economy and Finance, the President of the Economic Affairs Committee of the National Assembly, we wanted to be here to also show that we must look ahead and that in this health context, precisely on these health and pharmaceutical issues, France not only has assets but also a future and a future for reshoring.

We are here on an exceptional pharmaceutical industrial site, in a company that has shown all its strength and I really want to congratulate its CEO. Seqens is indeed a French flagship, a formidable mid-sized enterprise (ETI) that, in 15 years, has multiplied its presence on French soil. And in the world, precisely in active ingredients, it has shown its ability to mobilize and produce, and to grow from 3 to 14 sites in France, as you explained to me during the visit.

This mid-sized company is exemplary because it has been able to innovate in the field of active ingredients, because it has also been able to hire and innovate in social matters. We saw all its strength, with the few profiles that were presented to us here. It is a company that believes in the youth of our country, that has developed alternation, apprenticeships, that believes in its research and development and that, through a partnership logic, we saw in the project developed here with a partner, precisely based on an estrogen, developing an active ingredient to enable research, to move forward and build with its partner new medicines. So, I really want to emphasize the exemplary nature of this company.

But beyond the creation of this site, this production line that will allow us to be at the forefront of research in the sector, several dozen hires, the consolidation of the group, Seqens is also engaged in a process of reshoring. 12 molecules will be reproduced in France in the coming months and years through your commitment and the work that has been done with the Ministry of Economy and Finance and Health. 12 molecules, some of which, by the way, have sometimes been lacking or could have been lacking, we were in near shortage. I think of propofol, which we talked a lot about in March and April, at the peak of the epidemic.

And so it is very important in the strategy that is ours today that with our industrial partners, we succeed in reshoring. So, it is a word that we have often used. For some, it was an impossible dream. For others, a word not followed by actions. You demonstrate that action is there because there is collective work and it is work that did not start today or even yesterday.

The first pillar that makes these reshoring efforts possible is the work that has been done for 3 years. We have profoundly reformed capital taxation and thus investment in France. We have profoundly reformed the labor market which allows hiring, profoundly reformed also the apprenticeship sector which literally exploded before Covid, and which we are in the process of consolidating and this is part of the announcements that were also made a few days ago by the Prime Minister and the relevant ministers, and we have also profoundly accelerated a whole work around our industry. I remind you that at the beginning of the year, for the first time in over 10 years, we recreated industrial jobs in France and so this foundation of the last 3 years is what makes this wave of reshoring possible.

The second element is what has been done during the crisis, from the first day of the crisis, that is to say the work of resistance, of supporting the most struggling sectors. The Minister of Economy and Finance with the Prime Minister, piloted with all the sectoral ministers, 460 billion euros have been invested since the first day of the crisis, in state-guaranteed loans, in solidarity funds, in partial unemployment and in sectoral plans, from aeronautics to automotive to tourism. All of this, this resistance plan, is what then allows us to say: we will reshore when we can because when we let the industrial fabric or jobs or skills be lost at the peak of the crisis, it is very hard to claim later to reshore.

The third aspect is the one we are entering, which will be presented next week by the ministers at the end of the Council of Ministers on September 3. This is the famous recovery plan. It is in continuity with this work. And I want to reinsert it this way and in partnership with all sectors and industrialists, because it has been designed and made with industrialists so that these instruments meet the needs.

So, this recovery plan, this France Relance strategy that we are going to launch, is not a strategy to face the difficulties of the moment. We have already done that and we will continue for all sectors that justify it until the end of the year. No. It is to prepare France for 2030. It is not about subsidizing struggling sectors. We have done it wherever it was necessary and useful. It is about investing in the future, in accelerating our transformations, and our major transitions. It is about investing to transform, it is about building the France of tomorrow and therefore the France Relance project, which will be presented next week, is a project in which we want to project the country for more independence and therefore reshoring, to build a future model based on knowledge, on ecology and ecological transition, whether it is about the thermal renovation of buildings or sectors like hydrogen, and to build on skills, that is to say to invest in women and men, and particularly our youth. It is therefore a plan for investment in our future. It is a plan for investment in the French people, and particularly the youngest, to help them obtain a job in this very difficult period, to continue to have the necessary skills and training. This is the philosophy of this recovery plan, of this France Relance strategy that has been prepared for months.

In this context, reshoring plays a fundamental role for us. First, because it shows that there is no fatality and it is about building on future sectors like particularly the pharmaceutical sector, the capacity to reshore production. The 12 molecules I mentioned are behind R&D, the industrial process and the capacity to consolidate the production site in France, but also our collective capacity to provide medicines to our fellow citizens. We will do this through several actions.

First, simplification of our procedures. The temporary authorization for use, the famous ATUs that professionals in the sector know well, will be historically reformed and will be in place by January 1st, so that we will drastically reduce the timelines. We will be able to innovate more simply and more quickly in France. This is one of the shortcomings we historically had. We have been working on this for several months, even several years, with professionals in the sector, to allow for faster innovation, to bring to market even temporarily, more quickly, a medicine that is very promising in terms of innovation. This is essential to claim reshoring and to claim the development of new molecules, new medicines. The reform of ATUs on January 1st is a pillar of this France Relance. We are moving faster, we are simplifying. And investing is not just about money, it is about saving time for entrepreneurs, for industrialists and for their employees.

The second thing is that we will reduce the effort required each year from pharmaceutical companies by 300 million for the next Finance plan because, precisely, we need to give more leeway to this sector which is so strategic, whose importance we saw during the health crisis, and which is both to care for our fellow citizens today, but to build our competitiveness for tomorrow, a strategic sector for our country.

And then, we will invest massively in reshoring. In the recovery plan, which will be a little over 100 billion euros, there will be 15 billion for innovation and reshoring, and in particular one billion euros, really direct aid, built with industrialists to allow, on very specific projects, to provide state aid that helps to reshore, that is to say to sometimes compensate for a given time the small deficit we historically had and all of this obviously comes together with what was announced by the Prime Minister and the Minister of Economy and Finance a few days ago. It is the historic reduction of production taxes over the coming years that will improve the competitiveness of the production site in France, particularly in the industrial sector, and on everything that is productive and the most qualified.

So you see, it is this overall strategy that is important. And we are today alongside an industrialist who is innovating in a key sector and who will, thanks to France Relance, but also the will and commitment of its employees, massively reshore in the coming months and years.

This is the philosophy of this plan that I wanted to share with you today, before it is detailed next week and that in the coming weeks, with all our partners, we can then break it down so that as quickly as possible it allows us to build this France 2030 that allows us to be in this project of conquest and not simply in the management of the everyday.